Edwards Lifesciences (NYSE:EW) VP Sells $56,966.57 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $92.64 on Friday. The stock has a 50 day moving average price of $88.62 and a 200 day moving average price of $84.32. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The firm has a market capitalization of $53.34 billion, a P/E ratio of 53.24, a P/E/G ratio of 2.34 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the prior year, the company posted $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Institutional Trading of Edwards Lifesciences

Hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at $266,000. NewEdge Advisors LLC raised its position in shares of Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after acquiring an additional 2,665 shares in the last quarter. Sei Investments Co. lifted its stake in shares of Edwards Lifesciences by 16.7% during the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC lifted its stake in shares of Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina boosted its position in Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after purchasing an additional 1,065 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on EW shares. BTIG Research lifted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Truist Financial lifted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Evercore reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. UBS Group started coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target on the stock. Finally, Royal Bank Of Canada raised their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.